Financial news on March 16, 2008

Business and Financial news
Cutting Dosage of Costly Drug Spurs a Debate

A drug for a rare enzyme deficiency can cost $300,000 a year, making the right dose a matter of public debate. Read more..

By ANDREW POLLACK - The New York Times

Fed Chief Shifts Path, Inventing Policy in Crisis

Ben S. Bernanke, who has long argued that a central bank should act on consistent principles, now has to improvise. Read more..

By EDMUND L. ANDREWS - The New York Times

See what else happened on March 16, 2008